surmount-1 tirzepatide weight loss nondiabetic FDA Grants a New Indication for Obesity Management Tirzepatide and blood pressure reduction:

1 Upon analysis, results suggested the placebo-adjusted systolic blood pressure changes from baseline were 7.4 (95% CI, 10.0 to 4.7) mmHg, 10.6 (95% CI, 13.2 to 8.0) mmHg , and 8.0 (95% CI, 10.6 to 5.4) mmHg for tirzepatide 5, 10, and 15 mg, respectively

TRICARE beneficiaries who may qualify include: Active duty service members Family members of active duty personnel Retirees and eligible dependents Eligibility depends on enrollment in TRICARE plans and meeting medical necessity criteria

Patients are sold home treatment injections or do-it-yourself packs

The lowest dose is 2.5 mg once a week, and the maximum is 15 mg weekly